Cabometyx wins FDA approval for treating certain pancreatic cancers
The U.S. Food and Drug Administration (FDA) has granted its approval to the oral medication Cabometyx (cabozantinib) as a treatment for certain types of…
The U.S. Food and Drug Administration (FDA) has granted its approval to the oral medication Cabometyx (cabozantinib) as a treatment for certain types of…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Pep-Therapy‘s PEP-010, a potential first-in-class treatment for pancreatic cancer. The…
Treatment with the experimental cancer vaccine OSE2101, given in combination with standard chemotherapy, led to positive early results in a Phase 2 clinical trial…
Administering Silexion Therapeutics‘ investigational therapy SIL204 under the skin effectively reduced the growth of primary tumors and their metastatic spread to various organs in…
Treatment with CAN-2409, an immune-modulating anticancer therapy, showed promising trends toward improved survival in a Phase 2 clinical trial involving people with pancreatic cancer,…
Low muscle mass in people with inoperable pancreatic cancer undergoing chemoradiotherapy, or CRT, was linked with more treatment-related toxicities and shorter overall survival in…
A new blood test called PAC-MANN can detect the most common type of pancreatic cancer with high accuracy, according to a study led by…
Certain immunotherapies may be effective in some cases of pancreatic neuroendocrine neoplasms (Pan-NEN), a rare type of pancreatic cancer, according to a study that…
Treatment with the once-daily oral therapy lixumistat, in addition to chemotherapy, slowed the growth of pancreatic cancer among participants with advanced disease in an…
Treatment with certepetide in combination with standard therapies led to stable disease in most people with a type of pancreatic cancer known as…